Conference Coverage
Conference Coverage
‘Superior’ CLL regimen cuts chemo in half
Where chemo is still used to treat CLL, this three-cycle regimen combined with ibrutinib and obinutuzumab shows progression-free and overall...
Conference Coverage
Venetoclax combos prolong progression-free CLL survival
Time-limited targeted therapy with venetoclax plus obinutuzumab outperforms chemoimmunotherapy for CLL progression-free survival.
Conference Coverage
Novel gene therapy offers hope for some lymphomas
Novel CAR T-cell product shows promise for second-line treatment of relapsed and refractory lymphoma patients in a pilot study.
Conference Coverage
Glofitamab prevails against r/r DLBCL
Additional longer-term data showed a strong safety profile and promising long-term remission.
Conference Coverage
'New benchmark' set in phase-3 blood cancer study
Phase 3 SHINE study of older patients with mantle cell lymphoma yields “profound” results with ibrutinib add-on.
Conference Coverage
Studies address ibrutinib bleeding risk in patients with CLL receiving Mohs surgery
Mohs surgeons may commonly find themselves treating patients with these unique considerations.
Conference Coverage
Zanubrutinib shows worth against standard CLL drugs
New CLL drug demonostrates its efficacy in the crowded field of CLL treatment options.
News
When CPI fails, HL patients should get timely allo-HCT
New data suggest that physicians should refer Hodgkin lymphoma patients for allogeneic HCT without delay when PD-1 treatments fail.
Conference Coverage
DLBCL: PFS but no OS benefit with polatuzumab-vedotin add-on
Pending additional follow-up for overall survival, is the extra cost worth it?
Conference Coverage
‘Outstanding data’: Mosunetuzumab in r/r follicular lymphoma
If approved by the FDA, mosunetuzumab has the potential to be a first-in-class CD20xCD3 T-cell engaging bispecific antibody in non-Hodgkin...